pharma · Endometrial cancer · Specific Advanced Solid Tumors · ACRV
Acrivon Therapeutics
Acrivon Therapeutics is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker ACRV. Primary therapeutic focus areas include Endometrial cancer, Specific Advanced Solid Tumors, Endometrial
Cambridge, USA HQ
2018 Founded
84 Employees
Public company Type
ACRV · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2018
- Employees
- 84
- Programs
- 4
- Drugs
- 3
- Patents
- 0
ACR-368
Phase 2 · small molecule · Endometrial Adenocarcinoma
ACR-368 for Endometrial Adenocarcinoma is a Phase 2 program (small_molecule) at Acrivon Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code ACR-368-201 (GOG 3082)
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Acrivon Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Endometrial Adenocarcinoma
- Status
- active
- Trials
- 1